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Introduction
An invasive meningococcal disease (IMD)is a severe and a life-threatening disease caused by various Neisseria meningitidis serogroups, and it represents a serious public health problem worldwide, with an annual number of cases estimated to be at least 1.2 million [1] [2] [3] . In Europe, the USA and other industrialized regions, serogroups B and C are the major causes of IMDs [4, 5] . Approximately one in ten cases are fatal, and among those who survive, long-term sequelae, such as hearing loss, neurological defects or amputation, can occur [6, 7] . Vaccination practices (MenC and ACWY135 vaccines) have significantly changed the epidemiology of this disease, so that serogroup B is currently the predominant cause of IMDs in Europe, Latin America and North America [5, 8, 9] . In Italy, the IMD incidence is higher in children 0 to 4 years old than in the other age categories, particularly in infants less than 1 year old (IMD incidence = 4.01/100,000 in 2013) [10, 11] . The serogroup mainly involved in infants less than 1 year old is type B (IMD incidence = 3.44/100,000 in 2013), with the highest incidence among children younger than 24 months, peaking at 4-8 months [10, 12] . Between 2014 and 2016, the IMD incidence among individuals 15-24 years old increased, from 0.30/100,000 in 2014 to 0.90/100,000 in 2016, and decreased in adults older than 25 years during the same time period [10] . In Italy, the IMD surveillance system based on laboratory-confirmed cases (almost 70%) revealed that between 2011 and 2017, serogroup B was the most common IMD-causing type [10] , except between 2015 and 2016 when a hyper virulent meningococcal C strain was responsible for an unexpected increased IMD incidence in the Tuscany region. Following this episode, the Italian Health Authorities implemented immunization campaigns and enhanced IMD surveillance. On 14 January 2013, the European Medicines Agency authorized the use of the first vaccine available to protect against meningococcal serogroup B (Bexsero; GSK, Philadelphia, PA, USA) [13] [14] [15] [16] . It is a multicomponent vaccine (4CMenB) composed of three purified recombinant antigenic proteins from Neisseria meningitides serogroup B and the outer membrane vesicles of the bacterium. The 4CMenB vaccination schedule for infants consists of three doses: the first dose is given at three months old, the second dose is given between 1 and 2 months after the first dose, and the third "booster" dose is given at 13 months old. As with other vaccinations, the most common adverse reactions from the4CMenB vaccina-tion consist of fever, pain and swelling at the injection site, abnormal crying and irritability, eating disorders and gastrointestinal symptoms, sleepiness and a cutaneous rash. The uncommon adverse reactions consist of febrile or non-febrile convulsions and pallor, while the rarest adverse reactions are urticaria and Kawasaki syndrome [17] . The 4CMenB vaccination strategy differs across the European countries; for example, in Italy, the vaccination strategies are set out by different regions through the Regional Health Plan. This plan must respect the guidelines defined by the National Health Plan and the National Vaccine Prevention Plan (Piano Nazionale Prevenzione Vaccinale, PNPV) [18] . The latter defines the best vaccination policy to be carried out in each region in accordance with the best scientific evidence available. Each region can issue their own vaccination strategy in terms of the target population and costs that might being incurred by the citizens. This can lead to differences in the vaccine administration across Italian regions, resulting in heterogeneous vaccine coverage. The decreasing immunization adherence trend in Italy over recent years further compromises homogeneous and efficacious vaccine coverage, and this includes an unjustified fear of adverse reactions, scarce awareness regarding severe outcomes when not vaccinated, and the media's role in spreading incorrect information about vaccines. Many people's attitudes toward vaccinations may have been affected after an unverified association between the measles, mumps and rubella vaccine and autism was reported by the media, as well as after the Fluad case. The latter followed the withdrawal of the Novartis vaccine against influenza by the Italian Medicines Agency known as "Agenzia Italiana del Farmaco" after the occurrence of 3 deaths in 48 hours. Although there was prompt readmission of the Novartis vaccine, the media event had already affected people's attitudes towards vaccinations. These events have increased both citizens and healthcare workers' (HCWs) loss of faith in Italian institutions. Previous studies have documented the strong influence that HCWs have on a patient's decision making process regarding whether or not to undergo vaccination [19] [20] [21] [22] . However, some HCWs feel poorly informed and poorly trained on how to answer patient questions, and they often struggle when dealing with those who distrust the efficacy and safety of vaccines [23, 24] . Therefore, the aim of our study was to assess the knowledge and attitudes of HCWs involved in vaccination programs and infectious disease control with regard to recommending the 4CMenB vaccine in the Campania region of Italy.
Methods

Participants and setting
Within each Local Health Service (Aziende Sanitarie Locali, ASL) that manages public healthcare, the communicable disease prevention is run by two departments, the Maternal Childhood Health Protection Department, which delivers vaccines to children through its Maternal Childhood Operative Unit (Unità Operativa Materno Infantile, UOMI), and the Public Health Department, which looks at infectious disease surveillance and control through the Epidemiology Service (Servizio di Epidemiologia e Prevenzione) and Public Hygiene Service (Servizio di Igiene e Sanità Pubblica) and administers vaccines to adults and travellers through the Collective Prevention Operative Unit (Unità Operativa Prevenzione Collettiva). A cross-sectional study was conducted from 1 January 2017 through 30 June 2017 at the ASLs in the metropolitan areas of Naples, Caserta and Salerno in the Campania region among the HCWs involved in the surveillance and control of infectious diseases or vaccine administration (the total number of HCWs at these ASLs was around 750). In each unit, a healthcare operator was identified as a reference contact, and they collaborated to explain the study objectives and raise awareness among the HCWs. In addition, this individual distributed the questionnaires and collected them immediately after they were completed anonymously by the participants. The questionnaires focused on the HCWs' knowledge about IMD epidemiology and preventability and their attitudes towards 4CMenB vaccine use. It consisted of 45 items gathered into 3 main topics described as follows: 1. Socio-demographic information (sex, age, marital status, how many children, any children < 5 years old, education, degree type and medical specialty) and professional characteristics (ASL, workplace, occupational category, type of activity and seniority). 2. Knowledge about serogroup B meningococcal disease and the 4CMenB vaccine (epidemiology of meningococcal meningitis in Italy and its lethality and mortality rate, knowledge about the 4CMenB vaccination and its side effects). 3. Attitudes toward vaccination practices, specifically toward the 4CMenB vaccination (opinions about the 4CMenB vaccine, its efficacy and safety, the opportunity to recommend it and make it mandatory; opinions about the reasons why parents do or do not vaccinate their children), and updating resources (selfevaluation of their own level of knowledge about the 4CMenB vaccine and updating resources used).
Sample size
The number of HCWs needed was determined on the assumption that 75% of the HCWs had appropriate knowledge regarding IMDs and the 4CmenB vaccine, a confidence interval of 95% and a ratio unexp/exp 1:2. The results showed that a total number of 365 HCWs needed to be enrolled in the study.
Data analysis
The data was analysed 
Ethical considerations
All of the participants were informed that the data was collected anonymously and stored in a confidential manner. None of the participants could be identified based on the material submitted, and no incentives were offered to the HCWs for their participation in this study.
Results
A total of 293 HCWs completed the survey, with a response rate of 80.3%. As shown in Table I , 63.8% were women, 65.9% were between 41 and 59 years old, 79.2% were married, 83.6% had at least one child, 6.1% had a child less than 5 years old, 55.6% had graduated, and 7.4% and 88.9% had graduated from nursing and medicine, respectively. Among those who were physicians, the majority were specialists in hygiene and preventive medicine (35.2%), 21.4% were in paediatrics and just a few of them were specialists in infectious diseases (4.8%). Moreover, 50.8% of the HCWs worked in ASLs in Naples, 51.9% worked in UOMIs, the majority were physicians (49.5%), 46.4% were nurses and only 4.1% were other types of HCWs, like medical assistants, biologists and professional educators. Additionally, 51.9% of the participants were directly involved in vaccination programs, 17.1% were in infectious disease surveillance and control, and 23.2% were involved in both activities. Table II shows the results of the IMD knowledge among the physicians and nurses with relative confidence intervals; 24.1% of the physicians and 17.7% of the nurses reported that the meningococcal meningitis incidence in Italy was not high, while 50.3% of the physicians and only 38.2% of the nurses identified serogroup B as the most common. Regarding the age groups at a higher risk of contracting meningococcal meningitis, 27.3% of the HCWs indicated < 1 year old, 30.6% indicated from 1-4 years old and 27.3% indicated from 15-24 years old; however, only 7.6% of the physicians and 4.4% of the nurses indicated all three age groups that were at a higher risk (data not shown). Moreover, 80.4% of the HCWs indicated that the meningococcal meningitis lethality rate was high, while 48.3% and 36.0%,respectively, indicated that the mortality rate was very low. The results from the HCWs' knowledge about the 4CmenB vaccine are described in Table III . Most of the participants (69.0%) had at least sufficient knowledge about the 4CMenB vaccine, and 79.4% had sufficient knowledge about its vaccination schedule. However, only 34.1% of the HCWs indicated < 1 year old as the targeted group for the 4CMenB vaccination, while 18.2% and 20.5% indicated 1-4 years old and immunesuppressed individuals, respectively. Only 2.7% of the physicians and 2.9% of the nurses correctly identified all three targeted groups (results not shown). In order to assess their knowledge about the vaccination schedule, the HCWs were asked about the number of doses, timing and whether a booster shot was needed. Only 31.0% of the physicians and 21.3% of the nurses knew the 4CMenB vaccination schedule for all of the age groups. distrust that the parents had with regard to vaccinating their children had no scientific basis. Of the participants, 98.9% stated that HCWs must constantly be updated on vaccination-related scientific evidence, and 85.8% stated that they needed better information. In addition, the HCWs reported courses and conferences (30.5%) and the internet (26.2%) as their major sources of information about the 4CMenB vaccine. 
Discussion
This study was conducted after the 4CMenB vaccine was placed on the market. This vaccine specifically prevents serogroup B meningitis, which is the serogroup most frequently involved in this disease, and against which no traditionally made vaccines were previously available. Since its approval for use, many concerns about the most appropriate vaccination strategy have been raised within the international and national scientific communities [17] . In fact, in the years following the 4CMenB vaccine being placed on the market, the scientists and public health advisors in charge of health policies have had different opinions on how to provide the 4CMenB vaccine to the general population [14] . Therefore, the aim of the present study was to assess HCWs' knowledge about the 4CMenB vaccine and its vaccination strategy, while considering the role HCWs play in implementing vaccination coverage (whatever their position) within operative or decision-making units.
The present analysis determined that the majority of HCWs have sufficient knowledge about the lethality of the disease, but they are less informed about the incidence, higher risk age categories and most frequent serogroups involved. Many of them are confused about what is meant by mortality and lethality, and they mistakenly consider this disease to have a high mortality rate in the general population. The majority of the HCWs considered their knowledge about the vaccine and its vaccination schedule to be good, but only a few identified all of the targeted categories. This is particularly evident when considering immunosuppressed individuals, who are considered by the scientific community to be the group at highest risk and the most appropriate to receive the vaccine; however, they were identified as a target category by few of the HCWs. Moreover, some of the HCWs' answers were not consistent. For instance, one-third of the nurses believed that administering the 4CMenB vaccine with another vaccine enhanced the risk for adverse reactions, but only 15.0% indicated that the 4CMenB vaccine must be administered several days after another vaccine in order to reduce the risk for adverse reactions. Interestingly, those HCWs involved in surveillance and control activities had more knowledge about the epidemiological characteristics of the disease when compared with those working in the UOMI, where the HCWs are mainly involved in administering the vaccine to children. However, the HCWs working in the UOMI had better knowledge about the 4CmenB vaccination strategy and adverse reactions. It was unexpected that only a few of the HCWs knew about the PNPV (60.0% of the HCWs) and Campania Vaccine Prevention Plan (30.0% of the HCWs) indications about 4CmenB vaccine use, considering that both of these documents represent reference tools for HCWs. One limitation of this study was that the questionnaire was self-administered; therefore, we cannot be sure that the participants responded without having first been informed about the topics of interest. However, the results from the present analysis did show that the HCWs' knowledge was often partial and incorrect.
Overall, it must be noted that all of the HCWs were still convinced that vaccinations are important instruments for infectious disease prevention, and they were aware of the key role that they play in promoting 4CmenB vac- 
Conclusions
This study highlights the importance of and need to implement professional training courses for HCWs with interactive teaching methods. These should be suitable for an audience of experienced HCWs, as focus group, specific to the epidemiological aspects of meningococcal disease and the 4CmenB vaccine. These interventions would be useful for ensuring that HCWs are able to correctly answer patients' questions about the vaccine risks and benefits, because they represent the interface between public institutions and citizens [23] .
